SCHEMBL3670094

SCHEMBL3670094

CN1CC(=O)c2ccccc2C1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.50
MAOA P21397 3/20 0.47
MAOB P27338 3/20 0.47
CYP2A6 P11509 1/20 0.45
NPC1 O15118 3/20 0.44
RAB9A P51151 3/20 0.44
PKM P14618 2/20 0.43
NOTUM Q6P988 1/20 0.43
HTR2A P28223 3/20 0.42
HTR2C P28335 3/20 0.42
HTR2B P41595 3/20 0.42
SIGMAR1 Q99720 2/20 0.42
ACHE P22303 2/20 0.42
CES1 P23141 2/20 0.42
BCHE P06276 1/20 0.42
KDM4E B2RXH2 2/20 0.41
ALOX15 P16050 1/20 0.41
TSHR P16473 1/20 0.41
SIRT1 Q96EB6 1/20 0.41
CA12 O43570 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1649346 0.84 MAOA (0.56) KMT2AMAOAMAOBNPC1RAB9A
SCHEMBL19838638 0.82 MAOA (0.62) KMT2AMAOAMAOBCYP2A6HTR2A
SCHEMBL26608676 0.82 MAOA (0.62) MAOAMAOBCYP2A6HTR2AHTR2C
SCHEMBL130712 0.77 MAOA (0.71) MAOAMAOBNPC1RAB9ANOTUM
SCHEMBL24964880 0.74 MAOA (0.68) KMT2AMAOAMAOBNOTUMHTR2A
Bromide SCHEMBL2646357 0.74 MAOA (0.68) MAOAMAOBNPC1RAB9ANOTUM
SCHEMBL25634544 0.73 MAOA (0.65) MAOAMAOBHTR2AHTR2CHTR2B
SCHEMBL4987770 0.73 MITF (0.40) MAOAMAOBRAB9ASIGMAR1HTT
SCHEMBL21470732 0.73 MAOA (0.51) KMT2AMAOAMAOBNPC1RAB9A
SCHEMBL15779215 0.73 MEN1 (0.43) KMT2ACA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11186564-B2 Dual NAV1.2/5HT2a inhibitors for treating CNS disorders SUNOVION PHARMACEUTICALS INC. (US) 2021-11-30 US disclosed
US-20190194163-A1 DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS SUNOVION PHARMACEUTICALS INC. (US) 2019-06-27 US disclosed
US-9499531-B2 Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin ALBANY MOLECULAR RESEARCH, INC. (US) 2016-11-22 US disclosed
US-20150274713-A1 ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN CURIA GLOBAL, INC. 2015-10-01 US disclosed
EP-1778639-B1 ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN ALBANY MOLECULAR RES INC (US) 2015-09-02 EP disclosed
US-9085531-B2 Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin ALBANY MOLECULAR RESEARCH, INC. (US) 2015-07-21 US disclosed
US-20140243524-A1 ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN ALBANY MOLECULAR RESEARCH, INC. (US) 2014-08-28 US disclosed
US-8741901-B2 Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin ALBANY MOLECULAR RESEARCH, INC. (US) 2014-06-03 US disclosed
US-20130005965-A1 ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN BRISTOL-MYERS SQUIBB COMPANY (US) 2013-01-03 US disclosed
US-8236796-B2 Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin ALBANY MOLECULAR RESEARCH, INC. (US) 2012-08-07 US disclosed
EP-0845988-B1 NOVEL FUSED ISOQUINOLINES AS DOPAMINE RECEPTOR LIGANDS PURDUE RESEARCH FOUNDATION (US) 2001-12-05 EP disclosed
US-6194423-B1 CENTRAL NERVOUS SYSTEM DISORDERS PURDUE RESEARCH FOUNDATION 2001-02-27 US disclosed
US-5959110-A SUBSTITUTED TETRAHYDRO-1H-NAPH(1,2,3-DE)ISOQUINOLINE COMPOUND USEFUL FOR TREATING NERVOUS SYSTEM DISORDERS PURDUE RESEARCH FOUNDATION (US) 1999-09-28 US disclosed
CN-1199338-A Novel fused isoquinolines as dopamine receptor ligands PURDUE RESEARCH FOUNDATION (US) 1998-11-18 CN disclosed
US-4551474-A Methods of alleviating convulsions and pain employing 4-aryloxy-1,2,3,4 tetrahydroisoquinolines HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) 1985-11-05 US disclosed
US-4477670-A ANALGESICS, ANTICONVULSANTS HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) 1984-10-16 US disclosed
US-4410699-A ANALGESICS, ANTICONVULSANTS, HYPOTENSIVE AGENTS, DIURETICS HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) 1983-10-18 US disclosed
US-4375471-A ANTICONVULSANTS, ANALGERSICS HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) 1983-03-01 US disclosed
EP-0071919-A2 Spiro(benzofuran-2(3H),4'(2'H)-isoquinoline)s, a process for their preparation and their use as medicaments HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) 1983-02-16 EP disclosed
US-4374137-A ANALGESIC, ANTICONVULSANT, HYPOTENSIVE, DIURETIC HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) 1983-02-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190194163-A1 DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS SCN2A, HTR2A, HTR2C KMT2A 572/4885MAOA 94/4885MAOB 126/4885
US-20130005965-A1 ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN DRD4, SLC6A4, HTR4 KMT2A 1921/4885MAOA 102/4885MAOB 51/4885
US-20150274713-A1 ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN DRD4, SLC6A4, HTR4 KMT2A 1921/4885MAOA 102/4885MAOB 51/4885
US-11186564-B2 Dual NAV1.2/5HT2a inhibitors for treating CNS disorders SCN2A, HTR2A, HTR2C KMT2A 572/4885MAOA 94/4885MAOB 126/4885
US-20140243524-A1 ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN DRD4, SLC6A4, HTR4 KMT2A 1921/4885MAOA 102/4885MAOB 51/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.